PDE2A and Parkinson disease: In conclusion, both PDE inhibition via the PDE2A inhibitor PF05180999 and Gucy2C activation via guanylin effectively alleviate motor complications induced by dopamine deafferentation in the 6-OHDA Parkinson's disease mouse model, to a similar extent as the gold standard treatment, L-DOPA.